Results 51 to 60 of about 91,698 (296)

PARP inhibitors for homologous recombination-deficient prostate cancer [PDF]

Expert Opinion on Emerging Drugs, 2018
Prostate adenocarcinoma represents a leading cause of cancer-related mortality. Increased emphasis on understanding the molecular basis of prostate cancer has identified a substantial burden of homologous recombination (HR) pathway mutations, which are enriched in castrate-resistant disease.
Eric S, Christenson, Emmanuel S, Antonarakis   +1 more
openaire   +2 more sources

A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X. [PDF]

, 2008
BackgroundActivated factor X (FXa) is a vitamin K-dependent serine protease that plays a pivotal role in blood coagulation by converting prothrombin to thrombin. There are no reports of humans with complete deficiency of FX, and knockout of murine F10 is
Arruda, VR, Chu, K, Golden, JA, Herzog, RW, High, KA, Labosky, PA, Margaritis, P, Tai, SJ   +7 more
core   +2 more sources

Prediction of homologous recombination deficiency from cancer gene expression data

Journal of International Medical Research, 2022
Objective Homologous recombination deficiency (HRD) is the main mechanism of tumorigenesis in some cancers. HRD causes abnormal double-strand break repair, resulting in genomic scars.
Jun Kang, Jieun Lee, Ahwon Lee, Youn Soo Lee   +3 more
doaj   +1 more source

Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy [PDF]

, 2014
BRCA1, a key factor in homologous recombination repair may also regulate base excision repair (BER). Targeting BRCA1-BER deficient cells by blockade of ATM and DNA-PKcs could be a promising strategy in breast cancer.
Abdel-Fatah, TMA, Agarwal, D, Albarakati, N, Alsubhi, N, Arora, A, Ball, G, Caldas, C, Chan, S, Doherty, R, Ellis, IO, Green, A, Madhusudan, S, Moseley, P, Perry, C, Rakha, EA, Russell, R, Seedhouse, C   +16 more
core   +1 more source

Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. [PDF]

, 2010
The protein kinase Aurora-A is a major regulator of the cell cycle that orchestrates mitotic entry and is required for the assembly of a functional mitotic spindle.
Afshan McCarthy, Alan Ashworth, Chan Tang, Christopher J. Lord, Despina Maniotis, Giet R, Goggins M, Gritsko TM, Spiros Linardopoulos, Tony Sourisseau   +9 more
core   +2 more sources

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas [PDF]

Clinical Cancer Research, 2019
Abstract Purpose: The elevated levels of somatic copy-number alterations (SCNAs) in a subset of high-risk endometrial cancers are suggestive of defects in pathways governing genome integrity. We sought to assess the prevalence of homologous recombination deficiency (HRD) in endometrial cancers ...
Jonge, D, Auguste, A, Van Wijk, L, Schouten, P, Meijers, M, Ter Haar, N, Smit, V, Nout, R, Glaire, M, Church, D, Vrieling, H, Job, B, Boursin, Y, De Kroon, C, Rouleau, E, Leary, A, Vreeswijk, M, Bosse, T   +17 more
openaire   +3 more sources

Functional analysis of BARD1 missense variants in homology-directed repair and damage sensitivity [PDF]

, 2019
The BARD1 protein, which heterodimerizes with BRCA1, is encoded by a known breast cancer susceptibility gene. While several BARD1 variants have been identified as pathogenic, many more missense variants exist that do not occur frequently enough to assign
Adamovich, Aleksandra I, Banerjee, Tapahsama, Chen, Feng, Ding, Li, Duncan, Kathryn, Huang, Kuan-lin, Lee, Cindy, Ning, Jie, Parvin, Jeffrey D, Rodrigues, Fernanda Martins, Wingo, Margaret   +10 more
core   +3 more sources

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

JCO Precision Oncology, 2023
PURPOSE Homologous recombination deficiency (HRD) is highly prevalent in triple-negative breast cancer (TNBC) and associated with response to PARP inhibition (PARPi). Here, we studied the prevalence of HRD in non-TNBC to assess the potential for PARPi in a wider group of patients with breast cancer.
Synnøve Yndestad, Christina Engebrethsen, Andrea Herencia-Ropero, Oleksii Nikolaienko, Olav K. Vintermyr, Reidun K. Lillestøl, Laura Minsaas, Beryl Leirvaag, Gjertrud T. Iversen, Bjørnar Gilje, Egil S. Blix, Helge Espelid, Steinar Lundgren, Jürgen Geisler, Hildegunn S. Aase, Turid Aas, Einar G. Gudlaugsson, Alba Llop-Guevara, Violeta Serra, Emiel A.M. Janssen, Per E. Lønning, Stian Knappskog, Hans P. Eikesdal   +22 more
openaire   +5 more sources

Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities

Nature Communications, 2022
The molecular landscape of breast cancer brain metastases (BCBM) is still understudied, especially for different breast cancer subtypes. Here, the authors characterise subtype-specific BCBMs using genomics and transcriptomics and identify homologous ...
Nicola Cosgrove, Damir Varešlija, Stephen Keelan, Ashuvinee Elangovan, Jennifer M. Atkinson, Sinéad Cocchiglia, Fiona T. Bane, Vikrant Singh, Simon Furney, Chunling Hu, Jodi M. Carter, Steven N. Hart, Siddhartha Yadav, Matthew P. Goetz, Arnold D. K. Hill, Steffi Oesterreich, Adrian V. Lee, Fergus J. Couch, Leonie S. Young   +18 more
doaj   +1 more source

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment [PDF]

, 2016
Background: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience relapses with a median ...
Caruso, Davide, Papa, Anselmo, Strudel, Martina, Tomao, Federica, Tomao, Silverio   +4 more
core   +2 more sources